Cargando…
Peptide-Based Vaccines and Therapeutics for COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been prevalent in the humans since 2019 and has given rise to a pandemic situation. With the discovery and ongoing use of drugs and vaccines against SARS-CoV-2, there is still no surety of its complete suppression of this disease or if...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017722/ https://www.ncbi.nlm.nih.gov/pubmed/35463185 http://dx.doi.org/10.1007/s10989-022-10397-y |
_version_ | 1784688838216515584 |
---|---|
author | Bagwe, Pritam V. Bagwe, Priyal V. Ponugoti, Sai Srinivas Joshi, Shreerang V. |
author_facet | Bagwe, Pritam V. Bagwe, Priyal V. Ponugoti, Sai Srinivas Joshi, Shreerang V. |
author_sort | Bagwe, Pritam V. |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been prevalent in the humans since 2019 and has given rise to a pandemic situation. With the discovery and ongoing use of drugs and vaccines against SARS-CoV-2, there is still no surety of its complete suppression of this disease or if there is a need for additional booster doses. There is an urgent need for alternative treatment strategies against COVID-19. Peptides and peptidomimetics have several advantages as therapeutic agents because of their target selectivity, better interactions, and lower toxicity. Minor structural alterations to peptides can help prevent their fast metabolism and provide long-action. This comprehensive review provides an overview of different peptide-based vaccines and therapeutics against SARS-CoV-2. It discusses the design and mechanism of action of the peptide-based vaccines, peptide immunomodulators, anti-inflammatory agents, and peptides as entry inhibitors of SARS-CoV-2. Moreover, the mechanism of action, sequences and current clinical trial studies are also summarized. The review also discusses the future aspects of peptide-based vaccines and therapeutics for COVID-19. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-9017722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-90177222022-04-20 Peptide-Based Vaccines and Therapeutics for COVID-19 Bagwe, Pritam V. Bagwe, Priyal V. Ponugoti, Sai Srinivas Joshi, Shreerang V. Int J Pept Res Ther Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been prevalent in the humans since 2019 and has given rise to a pandemic situation. With the discovery and ongoing use of drugs and vaccines against SARS-CoV-2, there is still no surety of its complete suppression of this disease or if there is a need for additional booster doses. There is an urgent need for alternative treatment strategies against COVID-19. Peptides and peptidomimetics have several advantages as therapeutic agents because of their target selectivity, better interactions, and lower toxicity. Minor structural alterations to peptides can help prevent their fast metabolism and provide long-action. This comprehensive review provides an overview of different peptide-based vaccines and therapeutics against SARS-CoV-2. It discusses the design and mechanism of action of the peptide-based vaccines, peptide immunomodulators, anti-inflammatory agents, and peptides as entry inhibitors of SARS-CoV-2. Moreover, the mechanism of action, sequences and current clinical trial studies are also summarized. The review also discusses the future aspects of peptide-based vaccines and therapeutics for COVID-19. GRAPHICAL ABSTRACT: [Image: see text] Springer Netherlands 2022-04-19 2022 /pmc/articles/PMC9017722/ /pubmed/35463185 http://dx.doi.org/10.1007/s10989-022-10397-y Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Bagwe, Pritam V. Bagwe, Priyal V. Ponugoti, Sai Srinivas Joshi, Shreerang V. Peptide-Based Vaccines and Therapeutics for COVID-19 |
title | Peptide-Based Vaccines and Therapeutics for COVID-19 |
title_full | Peptide-Based Vaccines and Therapeutics for COVID-19 |
title_fullStr | Peptide-Based Vaccines and Therapeutics for COVID-19 |
title_full_unstemmed | Peptide-Based Vaccines and Therapeutics for COVID-19 |
title_short | Peptide-Based Vaccines and Therapeutics for COVID-19 |
title_sort | peptide-based vaccines and therapeutics for covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017722/ https://www.ncbi.nlm.nih.gov/pubmed/35463185 http://dx.doi.org/10.1007/s10989-022-10397-y |
work_keys_str_mv | AT bagwepritamv peptidebasedvaccinesandtherapeuticsforcovid19 AT bagwepriyalv peptidebasedvaccinesandtherapeuticsforcovid19 AT ponugotisaisrinivas peptidebasedvaccinesandtherapeuticsforcovid19 AT joshishreerangv peptidebasedvaccinesandtherapeuticsforcovid19 |